Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-973 in healthy adults
NCT05866055Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-973 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Adverse Events at Day 43. Started May 2023; status: completed.
02
Drugs
VX-973
03
Conditions
pain
Beyond the preview
Go deeper on NCT05866055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866055.